Updated Vasculitis Recommendations Include New Drugs, Practices Updated Vasculitis Recommendations Include New Drugs, Practices
Avacopan and mepolizumab feature in new European recommendations for managing antineutrophil cytoplasmic antibody-associated vasculitis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 2, 2022 Category: Consumer Health News Tags: Rheumatology News Source Type: news
What is in the Differential Diagnosis for Black and White Skin Conditions?
Discussion
This is the third in a short case series of differential diagnoses of colored skin conditions.
An introduction to dermatological terminologies and information about colors can be can be found here.
A differential diagnosis by distribution and common pattern can be found here.
For red, orange and yellow conditions, a review can be found here.
For green, blue and purple conditions, a review can be found here.
For brown and grey conditions, a review can be found here.
Note that any color can be a normal variant for an individual or is physiologic for a given state. When lesions of the opposite color of the normal s...
Source: PediatricEducation.org - May 9, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Rheumatoid Factor Positivity in ANCA-Associated Vasculitis Rheumatoid Factor Positivity in ANCA-Associated Vasculitis
What is the role of rheumatoid factor positivity in ANCA-associated vasculitis? A new study investigates.Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 4, 2022 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
What is in the Differential Diagnosis for Green, Blue or Violet Skin Conditions?
Discussion
Acrocyanosis is commonly seen in the newborn period as the baby transitions to extra-uterine life. It appears as blue-purple coloration of the distal extremities which usually improves over several hours.
Blue melanocytosis is also a common normal variant of skin color. It usually is seen on the posterior surface of the body around the spine and buttocks, but can also be on the upper parts of the extremities.
It is a blue-black coloration that shows a normal skin undertone when palpated.
This is the second in a short case series of differential diagnoses of colored skin conditions.
An introduction to dermatologi...
Source: PediatricEducation.org - May 2, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth in the first quarter of 2022
Basel, 25 April 2022Group sales increase 11%1 at constant exchange rates (CER) and 10% in Swiss francsPharmaceuticals Divisionsales up 6%; continued strong sales of new medicines for severe diseases. Impact of biosimilars decreases as expected.Diagnostics Divisionsales grow 24% due to good momentum in base business and continued high demand for COVID-19 tests. After a strong first quarter, significant decline in COVID-19-related testing expected.Highlights in the first quarter:FDA approval of Vabysmo (severe eye diseases); CHMP recommends EU approval of Polivy combination (aggressive form of blood cancer), Tecentriq (early...
Source: Roche Media News - April 25, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth in the first quarter of 2022
Group sales increase 11%1 at constant exchange rates (CER) and 10% in Swiss francsPharmaceuticals Divisionsales up 6%; continued strong sales of new medicines for severe diseases. Impact of biosimilars decreases as expected.Diagnostics Divisionsales grow 24% due to good momentum in base business and continued high demand for COVID-19 tests. After a strong first quarter, significant decline in COVID-19-related testing expected.Highlights in the first quarter:FDA approval of Vabysmo (severe eye diseases); CHMP recommends EU approval of Polivy combination (aggressive form of blood cancer), Tecentriq (early-stage non-small cel...
Source: Roche Investor Update - April 25, 2022 Category: Pharmaceuticals Source Type: news
Avacopan Shows Efficacy Signal for Rare Kidney Disease, C3G Avacopan Shows Efficacy Signal for Rare Kidney Disease, C3G
Avacopan, recently FDA approved for ANCA-associated vasculitis, showed significant benefit for reducing disease chronicity in a randomized trial of 52 patients with C3 glomerulopathy.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 7, 2022 Category: Allergy & Immunology Tags: Nephrology News Source Type: news
EULAR CVD Management Guidance Focuses on Gout, Lupus, Vasculitis EULAR CVD Management Guidance Focuses on Gout, Lupus, Vasculitis
The recommendations advise on managing cardiovascular health in patients with gout, vasculitis, systemic sclerosis, myositis, Sj ögren syndrome, lupus, antiphospholipid syndrome, and other diseases.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 24, 2022 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news
New two-year data for Roche ’s Vabysmo and Susvimo reinforce potential to maintain vision with fewer treatments for people with two leading causes of vision loss
This study will evaluate the efficacy, safety, and pharmacokinetics of the port delivery system with ranibizumab in participants with diabetic macular edema compared with intravitreal ranibizumab (Pagoda) [Internet; cited January 2022]. Available from:https://clinicaltrials.gov/ct2/show/NCT04108156.[14] ClinicalTrials.gov. A multicenter, randomized study in participants with diabetic retinopathy without center-involved diabetic macular edema to evaluate the efficacy, safety, and pharmacokinetics of ranibizumab delivered via the port delivery system relative to the comparator arm (PAVILION) [Internet; cited January 2022]. A...
Source: Roche Investor Update - February 11, 2022 Category: Pharmaceuticals Source Type: news
New two-year data for Roche ’s Vabysmo and Susvimo reinforce potential to maintain vision with fewer treatments for people with two leading causes of vision loss
This study will evaluate the efficacy, safety, and pharmacokinetics of the port delivery system with ranibizumab in participants with diabetic macular edema compared with intravitreal ranibizumab (Pagoda) [Internet; cited January 2022]. Available from:https://clinicaltrials.gov/ct2/show/NCT04108156.[14] ClinicalTrials.gov. A multicenter, randomized study in participants with diabetic retinopathy without center-involved diabetic macular edema to evaluate the efficacy, safety, and pharmacokinetics of ranibizumab delivered via the port delivery system relative to the comparator arm (PAVILION) [Internet; cited January 2022]. A...
Source: Roche Media News - February 11, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021
Basel, 3 February 2022Group sales increase 9%1 at constant exchange rates (CER); 8% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for newly launched medicines more than offsets impact of biosimilarsDiagnostics Divisionsales grow 29%; strong momentum in base business and continued high demand for COVID-19 testsMajor approvals for medicinessince the last quarter: United States: Susvimo and Vabysmo (age-related blindness)Europe: Gavreto (specific type of advanced lung cancer); Actemra/RoActemra (severe COVID-19); Ronapreve (non-hospitalised COVID-19 patients and prophylaxis)Major appro...
Source: Roche Investor Update - February 3, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021
Basel, 3 February 2022Group sales increase 9%1 at constant exchange rates (CER); 8% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for newly launched medicines more than offsets impact of biosimilarsDiagnostics Divisionsales grow 29%; strong momentum in base business and continued high demand for COVID-19 testsMajor approvals for medicinessince the last quarter:United States: Susvimo and Vabysmo (age-related blindness)Europe: Gavreto (specific type of advanced lung cancer); Actemra/RoActemra (severe COVID-19); Ronapreve (non-hospitalised COVID-19 patients and prophylaxis)Major approvals f...
Source: Roche Media News - February 3, 2022 Category: Pharmaceuticals Source Type: news
What are the Main Differences Between MIS-C and Kawasaki Disease?
Discussion
SARS-CoV-2 or COVID-19 was first observed in Wuhan China in late 2019. By March 2020 it had spread to become a world-wide pandemic and continues today despite vaccination and other public health measures. Early on people were worried that children would be the major age group affected, but the major groups were older individuals and those with underlying health problems. That is not to say that children are not affected as they were and could have severe disease. However as an overall group, they tend to get the virus and have less severe symptoms than adults. Severe disease is about 1% of pediatric cases compar...
Source: PediatricEducation.org - November 22, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
ADVOCATE: Avacopan Shows Renal Benefits in ANCA Vasculitis ADVOCATE: Avacopan Shows Renal Benefits in ANCA Vasculitis
The oral C5a receptor inhibitor could allow for the ' previously unthinkable ' avoidance of steroid treatment, and related adverse effects, in those with ANCA-associated vasculitis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 16, 2021 Category: Consumer Health News Tags: Nephrology News Source Type: news
FDA approves add-on drug for adults with rare form of blood vessel inflammation
FDA has approved Tavneos (avacopan) as an add-on treatment to standard therapy including glucocorticoids for adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. Tavneos helps to reduce blood vessel inflammation and offers patients an additional t (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 13, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
